Delivered Record Revenue and Adjusted EBITDA Ahead of Guidance Raises 2023 Guidance First quarter revenue of $120 million, up 16% year over year First quarter GAAP net income (loss) of ($18) million First quarter Adjusted EBITDA of ($6) million Updating …
미국 캘리포니아주 산호세, May 11, 2023 (GLOBE NEWSWIRE) -- 특허받은 혁신 기술로 엔터테인먼트의 탐색과 경험 방식에 대한 새로운 기준을 제시하는 Adeia Inc. (Nasdaq: ADEA)는 선도적인 셋톱박스 미들웨어 공급사인 TVStorm, Inc.이 한국 유료TV 시장의 고객사들을 지원하는 Adeia가 보유한 미디어 지식재산권(IP) 포트폴리오에 대한 라이선스 계약을 갱신했다고 발표했다. 이러한 다년간의 재계약을 통해 …
- Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab - - Received preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 …
FDA feedback from Type B meeting reiterated the Agency’s intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs) Phase 3 trial design is being finalized to support a broad label for IFIs …
ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation …
NEW YORK, May 10, 2023 (GLOBE NEWSWIRE) -- Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open web, helping people discover things they may like, today announced that members of its management team will present and host one-on- …
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase 1a clinical trial in healthy volunteers with safety data …
SHOEMAKERSVILLE, Pa., May 10, 2023 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment …
CANTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical …
- All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales - SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to …
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term investments of $197.7M at end 1Q 2023 - SEATTLE, May 10, 2023 ( …
Total Revenue Increases 12.0%; Company Comparable Restaurant Sales Increase 6.9%; Operating Margin Improves 360 Basis Points and Restaurant Contribution Margin Improves 400 Basis Points Compared to First Quarter 2022 BROOMFIELD, Colo., May 10, 2023 (GLOBE …
Continued Volume-Led Growth Driven by Rao’s Provides Strong Start to Fiscal 2023 Raising Full Year Net Sales and Adjusted EBITDA Guidance LOUISVILLE, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- Sovos Brands, Inc. (“Sovos Brands” or the “Company”) (Nasdaq: SOVO …
InteliSwab® test revenue of $118.3 million in Q1, up 33% sequentially; Company delivers cost savings and begins to taper InteliSwab® test production and expenses Gross margins increase 200 basis points sequentially despite mix/pricing headwinds Signs three …
VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications …
CERRITOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months …
Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML on track to report recommended Phase 2 dose and initial …
Continued progress on path to gross margin positive at a unit level by mid-2023 Reiterates guidance for full year 2023 LOS ANGELES, May 10, 2023 (GLOBE NEWSWIRE) -- Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leading electric truck manufacturer and …
First quarter performance consistent with prior guidance with Revenue of $16.8 million Net Loss of $5.1 million and negative Adjusted EBITDA1 of $3.4 million Record project backlog of $105 million as of March 31, 2023, as compared to backlog at the end of …
Third Quarter Net Revenue of $33.0 Million, Up 5 Percent Sequentially and 2 Percent Year over Year Third Quarter GAAP EPS of ($0.08) vs. ($0.09) in the Prior Year Third Quarter Non-GAAP EPS of $0.06 vs. $0.08 in the Prior Year IRVINE, Calif., May 10, 2023 …
01 days 11:50:08
